CAM
RPTX

Cormorant Asset Management’s Repare Therapeutics RPTX Stock Holding History

Cormorant Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-363,766
Closed -$11.3M – 99
2021
Q2 		$11.3M Sell
363,766
-98,439
-21% -$3.22M 0.39% 58
2021
Q1 		$14.2M Buy
462,205
+162,205
+54% +$5.51M 0.32% 60
2020
Q4 		$10.3M Sell
300,000
-48,567
-14% -$1.45M 0.24% 62
2020
Q3 		$10.7M Sell
348,567
-4,228
-1% -$112K 0.41% 55
2020
Q2 		$10.9M Buy
+352,795
New +$11.3M 0.42% 56

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cormorant Asset Management's RPTX Position: Q3 2021 in Review

Cormorant Asset Management sold out of Repare Therapeutics (RPTX) in Q3 2021, closing a stake of 363,766 shares — an estimated $11.3M sold.

Cormorant Asset Management first reported a position in RPTX in Q2 2020 and held it in 5 quarters. The position peaked at $14.2M in Q1 2021. 66 funds tracked by Wall St. Rank hold RPTX as of Q3 2021.

  • Cormorant Asset Management reported no remaining Repare Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 363,766 Repare Therapeutics shares in Q3 2021, an estimated $11.3M.
  • Cormorant Asset Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 5 quarters.
  • Cormorant Asset Management's Repare Therapeutics position peaked at $14.2M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.